UBS Equities-China Equity Strategy _Parallels with the 2015-16 recovery -...-107141624
Global Research and Evidence Lab Parallels with the 2015-16 recovery - what can we learn and what to do from here?
报告摘要
Global Research and Evidence Lab Parallels with the 2015-16 recovery - what can we learn and what to do from here?
报告信息
- 文件全名
- 《UBS Equities-China Equity Strategy _Parallels with the 2015-16 recovery -...-107141624.pdf》
- 适合读者
- 核心数据
- valuations. While the 2H15 episode saw a false start with the CSI 300 recovering 27%
- Overseas exposures have risen to c.15% of revenue from 12.5% in 2015, while gearing
- payout ratio is now at 33% vs 29% in 2015/2016 while trailing 12M buyback amount is
- also at a historical high at RMB260bn (c.0.3% of market cap but much higher for the
- drain on the equity markets. Earnings growth (8% for 2023 based on consensus
- 核心议题
常见问题
《UBS Equities-China Equity Strategy _Parallels with the 2015-16 recovery -...-107141624》主要包含哪些内容?
Global Research and Evidence Lab Parallels with the 2015-16 recovery - what can we learn and what to do from here?核心数据:valuations. While the 2H15 episode saw a false start with the CSI 300 recovering 27%;Overseas exposures have risen to c.15% of revenue from 12.5% in 2015, while gearing;payout ratio is now at 33% vs 29% in 2015/2016 while trailing 12M buyback amount is。
这份报告覆盖哪一年、篇幅多大?
覆盖 2024 年,全文共 23 页。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合投资人、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了IPO等议题。
继续阅读
查看全部 →